PD-1抑制治疗急性髓系白血病和骨髓增生异常综合征异基因移植后复发
这项前瞻性1B期临床试验纳入16例异基因造血干细胞移植后复发的急性髓系白血病(12例)和骨髓增生异常综合征(4例)患者,每3周给予帕博利珠单抗,评估移植物抗宿主病、临床反应和生存。总缓解率为31.3%,中位缓解持续时间610天;混合CD3嵌合患者缓解比例显著高于完全供者嵌合患者(50% vs 0%,P=0.03)。37.5%患者发生严重(3-4级)移植物抗宿主病,其中4例(25%)因此死亡。
要点
- 移植后复发患者接受帕博利珠单抗总缓解率31.3%,中位缓解持续时间610天。
- 混合CD3嵌合患者缓解比例显著高于完全供者嵌合患者(50% vs 0%,P=0.03)。
- 37.5%患者发生严重(3-4级)移植物抗宿主病,4例(25%)因此死亡。
核心结论
- 在该试验中,PD-1抑制使三分之一移植后早期复发患者获得持久缓解,提示该策略可能增强移植物抗白血病效应。
- 缓解仅见于混合CD3供者嵌合状态的患者。
- 免疫毒性(移植物抗宿主病)是成功治疗结局的障碍。
研究设计与样本
- 前瞻性1B期临床试验,纳入16例异基因造血干细胞移植后复发的急性髓系白血病(12例)和骨髓增生异常综合征(4例)患者。
- 每3周给予帕博利珠单抗,评估移植物抗宿主病、临床反应和生存。
- 移植后至复发的中位时间为5.5个月,治疗前骨髓原始细胞中位百分比为21.5%。
主要发现
- 接受帕博利珠单抗患者的总缓解率为31.3%,包括3例完全缓解(18.8%)和2例部分缓解(13.5%)。
- 中位缓解持续时间为610天。
- 混合CD3嵌合患者临床缓解比例显著高于完全供者嵌合患者(50% vs 0%,P=0.03)。
- 37.5%患者发生严重(3-4级)移植物抗宿主病,其中多数对糖皮质激素耐药,并导致4例(25%)患者死亡。
- 1年总生存率为37.5%,无事件生存率为31.3%;急性髓系白血病患者1年总生存率为50.0%。
关键数值与推荐
- 总缓解率31.3%,包括完全缓解18.8%和部分缓解13.5%。
- 中位缓解持续时间610天。
- 混合CD3嵌合患者缓解比例50% vs 完全供者嵌合患者0%(P=0.03)。
- 37.5%患者发生严重(3-4级)移植物抗宿主病,4例(25%)患者因此死亡。
- 1年总生存率37.5%,无事件生存率31.3%;急性髓系白血病患者1年总生存率50.0%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Relapse of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) remains the primary source of mortality after allogeneic hematopoietic stem cell transplantation (HCT). Targeting programmed death-1 (PD-1) for reversing T-cell exhaustion and restoring the graft-versus-leukemia (GVL) effect may have logistical advantages over donor lymphocyte infusion. In a prospective phase 1B clinical trial, pembrolizumab was administered every 3 weeks to 16 patients with AML (n = 12) and MDS (n = 4) in relapse after HCT to assess graft-versus-host disease (GVHD), clinical response, and survival. The median time to relapse after HCT was 5.5 months and the median pretreatment bone marrow blast percentage was 21.5%. The overall response rate was 31.3% for patients receiving pembrolizumab, consisting of 3 complete remissions (18.8%) and 2 partial remissions (13.5%). The median duration of response was 610 days. A significantly greater proportion of patients with mixed CD3 chimerism had a clinical response than those with full donor chimerism (50% vs 0%; P = .03). Immune toxicities were frequent, with 37.5% of patients developing severe (grade 3-4) GVHD after pembrolizumab, of which most had resistance to corticosteroids and contributed to death in 4 patients (25%). The 1-year overall survival (OS) was 37.5% and event-free survival was 31.3%. For AML, 1-year OS was 50.0%. In this trial, PD-1 inhibition led to durable remission in one-third of the patients experiencing early relapse after HCT, suggesting that this approach may augment the GVL response. Responses were exclusively observed in the setting of mixed CD3 donor chimerism. Immune toxicities (GVHD) were a barrier to successful treatment outcome. This trial was registered at www.ClinicalTrials.gov as #NCT03286114.
引用
- Magenau JM, Frame DG, Riwes M, et al. PD-1 inhibition for relapse after allogeneic transplantation in acute myeloid leukemia and myelodysplastic syndrome. Blood Adv. 2025. PMID: 40198769. doi:10.1182/bloodadvances.2024015200
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。